TNFRSF1A, Recombinant, Human, aa22-211, His-Tag (Tumor Necrosis Factor Receptor Superfamily Member 1A)
Catalog No : USB-218638
508.06€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | TNFRSF1A, Recombinant, Human, aa22-211, His-Tag (Tumor Necrosis Factor Receptor Superfamily Member 1A) | ||
|---|---|---|---|
| Catalog No | USB-218638 | ||
| Supplier’s Catalog No | 218638 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, E. coli | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 23.6 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Purified | ||
| Purity | ~85% (SDS-PAGE) | ||
| Form | Supplied as a liquid in 20mM Tris-HCl, pH 8.0, 10% glycerol. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | ~85% (SDS-PAGE) | ||
| Description | TNFRSF1A is a member of the TNF-receptor superfamily. This protein is one of the major receptors for the tumor necrosis factor-alpha. This receptor can activate NF-kappaB, mediate apoptosis, and function as a regulator of inflammation. Antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with this receptor, and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of this receptor were found to be associated with the autosomal dominant periodic fever syndrome. The impaired receptor clearance is thought to be a mechanism of the disease. Source: Recombinant protein corresponding to aa22-211 from human TNFRSF1A, fused to His-tag at N-terminus, expressed in E.coli. Molecular Weight: ~23.6kD (213aa) Applications: Suitable for use in SDS-PAGE. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
© 2020 Imugex All Rights Reserved